Login to Your Account

Late-Stage Pipeline Likely Unaffected

Anacor's Gram-Negative Drug Hits Snag; GSK Pauses Trials

By Marie Powers
Staff Writer

Tuesday, February 7, 2012
GlaxoSmithKline plc voluntarily suspended enrollment in Phase I and II trials of GSK2251052 (GSK'052), a systemic antibiotic for Gram-negative infections licensed from Anacor Pharmaceuticals Inc., due to a microbiological finding in patients enrolled in the Phase IIb in complicated urinary tract infections (cUTI).

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription